Business Context and Reporting Period
Company: Bausch Health Companies Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: A global, diversified specialty pharmaceutical and medical device company operating in gastroenterology, hepatology, neurology, dermatology, and eye health. The company operates through five reportable segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb (in which Bausch Health holds approximately 88% ownership). The company is actively pursuing the separation of its Bausch + Lomb eye health business into an independent entity, contingent on achieving targeted debt leverage ratios.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenues | $9,625 | $8,757 | $8,124 |
| Operating Income | $1,546 | $963 | $454 |
| Income (Loss) Before Taxes | $167 | $(390) | $(129) |
| Net Loss | $(72) | $(611) | $(212) |
| Net Loss Attributable to Bausch Health | $(46) | $(592) | $(225) |
| Operating Cash Flow | $1,597 | $1,032 | $(728) |
| Total Debt Obligations (Principal) | $20,480 | $21,006 | N/A |
| Cash and Cash Equivalents | $1,181 | $947 | $564 |
Segment Performance (2024 Revenue): Bausch + Lomb ($4,791M, 50%), Salix ($2,333M, 24%), International ($1,111M, 12%), Diversified ($950M, 10%), Solta Medical ($440M, 5%).
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 10% to $9.625 billion, driven by higher volumes, acquisitions (notably XIIDRA and MIEBO in Bausch + Lomb), and improved net realized pricing. This was partially offset by foreign currency impacts and divestitures.
- Operating Income Improvement: Operating income rose 61% to $1.546 billion. This improvement was primarily due to a $645 million increase in contribution margin and a $493 million decrease in goodwill impairments compared to 2023 (which included significant impairments in Dermatology, Neurology, and Generics). There were no goodwill impairments in 2024.
- Expense Increases: Selling, general, and administrative (SG&A) expenses increased by $379 million, largely due to higher selling and promotion costs for new Bausch + Lomb products. "Other expense, net" increased by $219 million, driven by adjustments to provisions for legal matters and acquired in-process R&D costs.
- Debt Reduction: The company repurchased and retired $555 million of senior unsecured notes in 2024. Total debt obligations decreased by $526 million from the prior year.
Guidance, Outlook, Risks, and Unusual Items
- B+L Separation: The separation of Bausch + Lomb remains a strategic priority but is subject to achieving targeted debt leverage ratios and shareholder approvals. The company is evaluating monetization options for its remaining B+L stake.
- Debt Maturities: Significant debt maturities are scheduled for 2025 ($2.38 billion) and 2026 ($767 million). The company has secured a $700 million bridge facility commitment to assist with liquidity needs. Management expects to remain in compliance with financial covenants for the next 12 months.
- Legal Proceedings: The company faces ongoing litigation regarding historical pricing practices and the B+L IPO. Notably, the company is engaged in "Xifaxan Generics Litigation" against multiple generic manufacturers. While the company successfully defended key patents in 2024, the outcome of ongoing proceedings could impact future cash flows. Accrued loss contingencies for legal matters totaled $332 million as of year-end.
- Regulatory Risks: The Inflation Reduction Act (IRA) poses pricing risks. In January 2025, the CMS selected Xifaxan 550 mg tablets for the second round of drug price negotiation, with initial price applicability in 2027.
- Acquisitions: Bausch + Lomb completed several acquisitions in 2024, including Elios Vision, Trukera Medical, and Whitecap Biosciences (Jan 2025), to bolster its glaucoma and dry eye portfolios.
Key Facts for Investor Verification
- Debt Covenant Compliance: Verify the company's ability to meet the first lien leverage ratio covenant under the 2022 Amended Credit Agreement, given the $2.38 billion debt maturity in 2025.
- Xifaxan Litigation Status: Monitor the status of the Norwich II and other generic litigation regarding Xifaxan, which represents approximately 85% of Salix segment revenue and 21% of total company revenue.
- B+L Separation Timeline: Confirm progress on the debt leverage targets required to finalize the Bausch + Lomb separation and the potential monetization of the remaining 88% stake.
- Goodwill Impairment Risk: Assess the "headroom" in reporting units (specifically Dermatology and Generics) which had limited or no headroom in prior tests, making them susceptible to future impairment charges if market conditions deteriorate.
- IRA Price Negotiation Impact: Evaluate the potential financial impact of the CMS selection of Xifaxan for price negotiation under the Inflation Reduction Act starting in 2027.